2 new Covid vaccines granted emergency authorization in India

Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare has given emergency use authorization approval to COVID19 vaccines Covovax & Corbevax and Anti-viral drug Molnupiravir, said Health Minister Dr.Mansukh Mandaviya on Tuesday, according to ANI.

US biotechnology company Novavax’s protein-based Covid-19 vaccine, NVX-CoV2373, is being locally manufactured by Pune-based Serum Institute of India under the brand name Covovax. Corbevax or BioE COVID-19, is a COVID-19 vaccine candidate developed by Indian biopharmacutical firm Biological E. Limited (BioE), the Baylor College of Medicine in Houston, United States, and American company Dynavax Technologies (DVAX). It is a protein subunit vaccine. Molnupiravir is an anti-viral drug that is made by American Pharmaceutical Company Merck & CO. This is an oral drug.

The Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting emergency use authorisation to the Serum Institute of India’s Covid-19 vaccine Covovax and Biological E’s vaccine Corbevax with certain conditions.

The panel also recommended granting permission to manufacture and market anti-Covid pill Molnupiravir for restricted emergency use for the treatment of adult patients.